

INTERNATIONAL JOURNAL OF  
**Cardiovascular  
SCIENCES**

International Journal of Cardiovascular Sciences

ISSN: 2359-4802

ISSN: 2359-5647

Sociedade Brasileira de Cardiologia

Karakayalı, Muammer; Artac, Inanc; Ilis, Dogan; Omar, Timor; Altunova, Mehmet; Guzel, Ezgi; Rencüzoğulları, İbrahim; Karabağ, Yavuz  
Evaluation of Symptomatic and Asymptomatic Outpatients in the Post-COVID-19 Period  
With Electrocardiographic Ventricular Depolarization and Repolarization Parameters  
International Journal of Cardiovascular Sciences, vol. 37, e20230105, 2024  
Sociedade Brasileira de Cardiologia

DOI: <https://doi.org/10.36660/ijcs.20230105>

Available in: <https://www.redalyc.org/articulo.oa?id=726077615025>

- ▶ How to cite
- ▶ Complete issue
- ▶ More information about this article
- ▶ Journal's webpage in redalyc.org

 redalyc.org

Scientific Information System Redalyc

Network of Scientific Journals from Latin America and the Caribbean, Spain and Portugal

Project academic non-profit, developed under the open access initiative

## ORIGINAL ARTICLE

## Evaluation of Symptomatic and Asymptomatic Outpatients in the Post-COVID-19 Period With Electrocardiographic Ventricular Depolarization and Repolarization Parameters

Muammer Karakayali,<sup>1</sup> Inanc Artac,<sup>1</sup> Dogan Ilis,<sup>1</sup> Timor Omar,<sup>1</sup> Mehmet Altunova,<sup>2</sup> Ezgi Guzel,<sup>1</sup> İbrahim Rencüzoğulları,<sup>1</sup> Yavuz Karabağ<sup>1</sup>

Kafkas University Faculty of Medicine,<sup>1</sup> Kars – Turkey

Istanbul Mehmet Akif Ersoy Training and Research Hospital,<sup>2</sup> Istanbul – Turkey

### Abstract

**Background:** A recently identified viral illness called coronavirus disease 2019 (COVID-19) is spreading quickly. Numerous cardiovascular issues such as arrhythmias and electrocardiogram (ECG) alterations have been linked to COVID-19.

**Objective:** In this investigation, we compared ECG indicators of depolarization and repolarization heterogeneity between symptomatic individuals who complained of palpitations and chest discomfort following COVID-19 and those who did not.

**Methods:** In this prospective case-control study, 56 post-COVID-19 patients who did not have any symptoms of chest discomfort or palpitations were included in the control group and compared with a study group comprising 73 post-COVID-19 patients who presented at the outpatient clinic with complaints of chest pain and palpitation. Electrocardiographic (ECG) measures were used to assess depolarization and repolarization of the ventricles. These measures included the Tpeak-Tend (Tp-e) interval, QT dispersion (QTd), Tp-e/QT ratio, Tp-e/QTc ratio, frontal QRS-T (fQRS-T) angle, and fragmented QRS (FQRS). Two cardiologists recorded the patients' ECG data. A statistically significant result was defined as a p value less than 0.05.

**Results:** The results of multivariate analysis including FQRS, Tp-e interval, Tp-e/QT, and Tp-e/cQT showed that presence of FQRS (OR: 6.707, 95% CI: 1.733-25.952; p = 0.006) was an independent predictor of symptomatic post-COVID-19 patients.

**Conclusion:** In our study, FQRS was found to be significantly higher in symptomatic post-COVID-19 patients than in non-symptomatic post-COVID-19 patients, while Tp-e interval was found to be lower.

**Keywords:** COVID-19; cardiac Arrhythmias; Electrocardiography.

### Introduction

The coronavirus disease 2019 (COVID-19) is caused by the coronavirus family's seventh member, which can infect humans.<sup>1</sup> The first instance of COVID-19 was discovered in December 2019 in Wuhan, China, and the sickness quickly spread to all countries, causing a terrible epidemic. COVID-19 has been linked to serious cardiovascular complications.<sup>2</sup> A significant body of study has been conducted to identify possible risk factors for serious adverse cardiac events. Following

COVID-19, many individuals seek treatment at cardiology outpatient clinics for chest discomfort and palpitations. Many of these people have no risk factors for cardiovascular disease or a history of cardiac or arrhythmic disease".<sup>3</sup>

QT dispersion (QTd), the interval between T wave peak and T wave tip (Tp-e), and the frontal QRS-T (fQRS-T) angle have all been proposed as indications of regional and transmural heterogeneity of cardiac repolarization. It has been found that systemic viral

#### Mailing Address: Muammer Karakayali

Kafkas University Faculty of Medicine, Cardiology. Merkez/KARS, 36100. Kars – Turkey  
E-mail: muammer-28@hotmail.com

**Central Illustration: Evaluation of Symptomatic and Asymptomatic Outpatients in the Post-COVID-19 Period With Electrocardiographic Ventricular Depolarization and Repolarization Parameters**

The study group consisted of 73 consecutive post-COVID patients evaluated in the outpatient clinic with ECG for indications of palpitation and chest pain within 12 to 26 weeks following diagnosis of COVID-19 (post-COVID period). Symptoms may persist for up to 12 weeks after COVID (ongoing symptomatic COVID). The control group consisted of 55 consecutive patients with asymptomatic COVID-19 who had no palpitation or chest pain and no cardiovascular disease or risk factors.

Tp-e interval, QTd, Tp-e/QT ratio, Tp-e/QTc ratio, fQRS-T and FQRS angle were evaluated as ECG measures. Medical comorbidities, physical examination findings, laboratory findings, and standard 12-lead ECGs obtained on the day of the index outpatient visit for all patients were recorded for analysis.

Patients with uninterpretable ECG, complete bundle branch block, nonsinus rhythms (e.g., atrial fibrillation), symptoms of acute coronary syndromes, symptomatic heart failure with EF  $\leq$  50%, outpatient use of QT-prolonging agents (e.g., fluoroquinolones, azithromycin, etc.) and electrolyte imbalances on admission were excluded. Furthermore, individuals identified as having LVH on their echocardiography records were eliminated from the research, as this condition might affect the fQRS-T angle values. In addition, patients with a history of serious COVID-19 illness requiring hospitalization were excluded.

In conclusion, in our study, FQRS and lower Tp-e interval were found more frequently in symptomatic post-COVID-19 patients compared to asymptomatic post-COVID-19 patients and FQRS and Tp-e were found to be independent predictors in the symptomatic group. We believe that FQRS may be effective for identifying a group that may be symptomatic among outpatient COVID-19 patients who have not had serious illness.

Int J Cardiovasc Sci. 2024; 37:e20230105

ECG: electrocardiogram; Tp-e: Tpeak-Tend; QTd: QT dispersion; fQRS-T: frontal QRS-T; FQRS: fragmented QRS; EF: ejection fraction; QTc: corrected QT.

infections<sup>4</sup> and systemic inflammatory disorders<sup>5</sup> have a significant impact on these ECG indicators. However, the effect of COVID-19 on cardiac repolarization is not well understood. Unlike prior research, this study was designed to look at the influence of repolarization and depolarization heterogeneity on several ECG markers in post-COVID-19 symptomatic patients vs. non-symptomatic COVID-19 patients.

The presence of an extra R wave (R'), a notch at the end of the R or S wave, or more than one R' in at least two consecutive leads that correspond to the regions supplied by the main coronary arteries are characteristics of fragmented QRS (FQRS), a depolarization disorder.<sup>6</sup> A wide range of cardiac disorders, including coronary artery disease (CAD), cardiomyopathies, valvular heart disease, aortic dissection, pulmonary embolism, congenital heart disease, and cardiac channelopathies, have been studied in the literature on fQRS during the past several years.<sup>7</sup> It was shown that patients with

FQRS on surface ECGs had higher death rates and worse prognosis.<sup>8</sup>

The aim of this study was to evaluate the electrocardiogram (ECG) markers of depolarization and repolarization heterogeneity in symptomatic patients presenting to the outpatient clinic with post-COVID palpitations and compare them to the same markers in post-COVID-19 patients without these symptoms.

## Methods

### Study participants

The research group was made up of 73 consecutive post-COVID patients who were assessed using an ECG in the outpatient clinic for signs of palpitations and chest discomfort between 12 and 26 weeks after being diagnosed with COVID-19 (the post-COVID period). Symptoms may still be present up to 12 weeks following COVID (ongoing symptomatic COVID).

The control group was made up of 55 consecutive individuals with COVID-19 who were asymptomatic, free of chest discomfort or palpitations, and had no cardiovascular disease or risk factors. The sample size of our investigation was determined using data from a study by Yenerçag et al.<sup>9</sup>

Electrocardiographic measures included Tpeak-Tend (Tp-e) interval, QTd, Tp-e/QT ratio, Tp-e/QTc ratio, fQRS-T, and FQRS angle (Nihon Kohden, Tokyo, Japan). For analysis, all patients' medical comorbidities, physical examination results, laboratory results, and standard 12-lead ECGs acquired on the day of their index outpatient visit were documented.

All patients had transthoracic echocardiography utilizing Philips HD 11 XE ultrasound equipment (Andover, MA, USA).

Individuals who exhibited symptoms of acute coronary syndromes, complete bundle branch block, nonsinus rhythms (like atrial fibrillation), symptomatic heart failure with ejection fraction (EF)  $\leq$  50%, outpatient use of QT-prolonging agents (like azithromycin, fluoroquinolones, etc.), and/or electrolyte imbalances upon admission were excluded. Moreover, participants with LVH noted on their echocardiogram reports were excluded from the study since this illness may have an impact on the fQRS-T angle readings. Furthermore, those who had previously experienced severe COVID-19 disease that necessitated hospitalization were not included.

### ECG recordings

All patients had 12-lead ECG (Nihon Kohden, Tokyo, Japan) recorded at rest in the supine position with speed of 25 mm/s, height of 10 mm/mV, and filter range of 0.16–100 Hz. Surface ECGs were scanned and imported into Adobe Photoshop CC 2019 (Adobe Photoshop Version: 20.0.0; Adobe Inc.) on a desktop computer. After setting the measurement scales, intervals were computed at 200% magnification.

Clinical ECG equipment cannot identify the spatial QRS-T angle due to their three-dimensional nature and lack of a vector that displays the postero-anterior axis of the heart. As a result, the spatial QRS-T angle—which was appropriate when utilizing 12-lead ECG—was replaced with the fQRS-T angle.<sup>10,11</sup> The fQRS-T angle was simply computed by subtracting the QRS angle from the T angle in the ECG because the majority of ECG machines automatically provide

the QRS and T axes. The Tp-e interval was established from the T wave's peak until its termination. The longest Tp-e interval was reported by measuring the Tp-e interval from precordial leads.<sup>12</sup> In cases with complex T waves (biphasic, triphasic, etc.), the interval between the nadir of the first component of the T wave and the end of the T wave was measured.<sup>13,14</sup> The time elapsed between the start of the QRS complex and the conclusion of the T wave was named the QT interval. All leads had their QT intervals measured, and the longest QT interval was noted. The difference between the greatest and minimum QT interval in several leads was used to calculate QTd. Heart rate was calculated using the measured R-R interval. Bazett's formula ( $QTc = QT\sqrt{(R-R \text{ interval})}$ ) was used to compute the corrected QTd and corrected QT interval (QTc). These values were used to determine the Tp-e/QT ratios. In a standard 12-lead ECG (0.5–150 Hz), FQRS is defined as the presence of extra R' waves or a notch in the nadir of the R or S wave (fragmentation) in two contiguous leads belonging to a coronary region. Two different cardiologists measured patients' ECG data. These values were computed for every research subject. When there was substantial disagreement, a third independent cardiologist calculated the ECG parameters, and the results were agreed upon. The intraclass correlation coefficients for both intraobserver and interobserver variability were greater than 95% for every measurement assessed.

### Statistical analyses

The SPSS 22.0 statistical package for Windows, (SPSS Inc., Chicago, IL, USA) was utilized for all statistical analyses. The Kolmogorov-Smirnov test was utilized to determine whether distributions were normal. The mean  $\pm$  standard deviation was used to specify quantitative variables with normal distribution, whereas the median (interquartile range) was used to specify variables with irregular distribution. Counts and percentage values were displayed for categorical variables. The Mann Whitney U test and Student's *t* test (unpaired) were used to assess group differences. The chi-square test was used to compare categorical variables. Using factors that were significant in univariate analysis ( $P < .05$ ), multivariate logistic regression (stepwise backward conditional) analysis was performed to identify independent predictors of the sample group. A statistically significant result was defined as a *p* value less than 0.05.

## Results

A total of 128 patients with a history of COVID-19 were included in the final analyses. Of these patients, 73 were in the symptomatic group with complaints of chest pain and palpitation and 55 were in the asymptomatic group. The general characteristics of the patients are shown in Table 1. There were no significant differences between the groups in terms of clinical characteristics or hematological or biochemical parameters, except for smoking status (3 (5.5%) vs. 3 (17.8%),  $p = 0.037$ ) and ALT levels (23 (13-26) vs. 19 (13-21),  $p = 0.024$ ).

When we compare the ECG parameters between the two groups (Table 2), there were no significant differences between groups for QRS duration, QT interval, cQT interval, QTd, or fQRS-T angle. There were significant differences between the groups in terms of Tp-e interval, Tp-e/QT, Tp-e/cQT, and FQRS. Tp-e interval, Tp-e/QT, and Tp-e/cQT were found to be higher in asymptomatic post-COVID-19 patients, with statistically significant differences. In contrast, FQRS was detected in more patients in the symptomatic group.

The results of multivariate analysis of FQRS, Tp-e interval, Tp-e/QT, and Tp-e/cQT showed that FQRS (OR: 6.707, 95% CI: 1.733-25.952;  $p = 0.006$ ) and Tp-e interval (OR:0.880, 95% CI: 0.788-0.983;  $p = 0.023$ ) were independent predictors of symptomatic post-COVID-19 patients (Table 3).

## Discussion

To the best of our knowledge, this study is the first in the literature to compare ECG ventricular depolarization and repolarization parameters between symptomatic and asymptomatic groups of post-COVID patients. To summarize the main findings of our study, presence of FQRS and a lower Tp-e interval were found in more patients whose symptoms continued after COVID-19 disease than in asymptomatic patients.

Tp-e interval and Tp-e/QT ratios have been utilized as event predictors in several clinical situations, such as cardiac failure, Brugada syndrome, hypertrophic cardiomyopathy, and bradyarrhythmia and even in the general population. In comparison to a healthy control group, Yenerçag et al. found that patients with COVID-19 infection had longer Tp-e intervals and higher Tp-e/QT and Tp-e/QTc ratios before initiation of therapy.<sup>9</sup> Conversely, our research revealed statistically significant differences in Tp-e interval, Tp-e/QT, and

**Table 1– Comparison of demographic features and laboratory characteristics of asymptomatic and symptomatic post-COVID-19 patients**

	Asymptomatic post-COVID-19 patients (n = 55)		Symptomatic post-COVID-19 patients (n = 73)		p
Age (years)	41	±13	38	±11	0.306
Sex, n (%) (Female)	23	(41.8)	41	(56.2)	0.109
Smoking, n (%)	3	(5.5)	13	(17.8)	0.037
Hypertension, n (%)	8	(14.5)	7	(9.5)	0.390
Diabetes, n (%)	3	(5.4)	4	(5.4)	0.995
Hemoglobin (g/dL)	14.55	±1.71	14.49	±1.84	0.832
Htc (%)	43.45	±4.81	43.73	±4.85	0.743
WBC (10 <sup>3</sup> /mL)	7.23	±1.76	7.40	±1.99	0.711
Lymphocytes (10 <sup>3</sup> /mL)	2.28	(1.82-2.65)	2.29	±0.79	0.878
Platelets (10 <sup>3</sup> /mL)	269	±74	280	±61	0.337
Glucose (mg/dL)	104	±31	94	±21	0.055
Creatine (mg/dL)	0.74	±0.24	0.74	±0.18	0.686
eGFR (mL/min/1.73 m <sup>2</sup> )	105.09	±17.42	107.88	±17.40	0.227
ALT (U/L)	23	(13-26)	19	(13-21)	0.024
AST (U/L)	20	±10	18	±5	0.954
CRP (mg/L)	1.69	(0.68-5.72)	1.82	(0.80-3.50)	0.939
Sodium (mEq/L)	139	±3	139	±2	0.645
Potassium (mEq/L)	4.27	±0.39	4.20	±0.37	0.402
Calcium (mg/dL)	9.49	±0.48	9.33	±0.42	0.344
TSH (mIU/L)	1.62	(1.31-2.39)	1.55	(2.35-2.27)	0.879
T3 (nmol/L)	3.38	±0.59	3.11	±0.61	0.893
T4 (nmol/L)	1.28	±0.26	1.34	±0.47	0.687

ALT: Alanine Transaminase; AST: Aspartate Transferase; WBC: White Blood Cells, Htc: Hematocrit; eGFR: Estimated Glomerular Filtration Rate; TSH: Thyroid Stimulating Hormone; T3: Triiodothyronine; T4: Thyroxine; CRP: C-Reactive Protein.

**Table 2 – Comparison of electrocardiographic (ECG) findings of groups.**

	Group 0 (Asymptomatic post-COVID-19 patients)		Group 1 (Symptomatic post-COVID-19 patients)		P
Heart rate, bpm	82	±15	83	±16	0.992
QRS duration, ms	93	±11	94	±14	0.630
Tp-e interval, ms	65	±9	61	±14	0.009
QT interval, ms	382	±31	376	±32	0.284
cQT interval, ms	439	±26	433	±27	0.139
QTd, ms	56	±19	53	±20	0.431
Tp-e/QT	0.17	±0.03	0.16	±0.04	0.031
Tp-e/cQT	0.15	±0.02	0.14	±0.03	0.034
FQRS, n(%)	3	(5)	16	(22)	0.01
fQRS-T angle (°)	41	(13-60)	39	(14-53)	0.925

*Tp-e: peak-to-end interval of the T wave; cQT interval: corrected QT interval; FQRS: Fragmented QRS; fQRS-T angle: frontal QRS-T angle; QTd: QT dispersion.*

**Table 3 – Logistic regression models for post-COVID-19 patients**

	Univariate		Multivariate		P
	Univariate OR, 95% CI	P	Multivariate OR, 95% CI	P	
Tp-e interval	0.968 (0.937-0.999)	0.04	0.880 (0.788-0.983)	0.023	
Tp-e/ QT	0.000 (0.000-6.376)	0.102	-	-	-
Tp-e/ cQT	0.000 (0.000-10.700)	0.111	-	-	-
FQRS	4.865 (1.341-17.660)	0.016	6.707 (1.733-25.952)	0.006	

*Tp-e: peak-to-end interval of the T wave; cQT interval: corrected QT interval; FQRS: Fragmented QRS; OR: odds ratio; CI: confidence interval.*

Tp-e/cQT between asymptomatic and symptomatic post-COVID-19 individuals. The biggest difference in our study was that the control group consisted of patients with a history of COVID-19 infection, even if they had been asymptomatic, rather than a healthy control group. For this reason, different results were obtained for the ventricular repolarization markers Tp-e interval, Tp-e/QT, and Tp-e/cQT between symptomatic and asymptomatic post-COVID-19 patient groups compared to other studies including healthy control groups. We think that there is a need for studies of this subject involving more patients and centers.<sup>15</sup>

QT interval prolongation is a traditional ECG indicator of vulnerability to torsades de pointes (TdP) or malignant arrhythmias. Handheld devices can streamline monitoring for COVID-19 patients, particularly those on QT-prolonging medications like azithromycin or hydroxychloroquine for SARS-CoV-2.<sup>16</sup> However, in our study, no significant difference was found between the groups in terms of QT or cQT intervals. We think that this may be due to the fact that our patient groups consisted of outpatients who did not have serious COVID-19 infections and therefore did not use drugs that prolong the QT interval.

Elevated Alanine Transaminase (ALT) levels have been detected in COVID-19 disease, especially due to hypoxic and drug toxicity, depending on the severity of the disease.<sup>17</sup> Our study and control groups were outpatients with no history of serious COVID-19 infection and were seen at least 12 weeks after the COVID-19 disease. However, while there was a significant difference between groups in ALT levels, median ALT levels were within the normal reference range in both groups.

A typical ECG recording can be used to quickly identify FQRS, a depolarization condition. It represents the myocardium's fibrotic tissue-induced conduction delay.<sup>6</sup> Research has demonstrated a correlation between myocardial scarring and FQRS, which is seen in the superficial ECGs of patients with CAD or suspected CAD.<sup>18</sup> According to one study, f-QRS was detected in 24.2% of patients with COVID-19.<sup>19</sup> In our study, a similar rate was found in symptomatic post-COVID-19 patients (22%). Interestingly, the rate in asymptomatic post-COVID-19 patients was low, at 5%. Although a relationship between FQRS and the severity of COVID-19 disease has been proven,<sup>20</sup> we think that as shown in our study it may be effective for identifying a group that may be symptomatic among COVID-19 patients who have not had serious illness. In a recently

published paper, Yildirim et al.<sup>8</sup> studied 114 patients with COVID-19. Especially in patients with COVID-19, FQRS was been found to be an indicator of poor clinical outcomes. In another retrospective study, Bektas et al. suggested that presence of FQRS in patients with COVID-19 may be useful for predicting cardiovascular outcomes.<sup>19</sup> In our study, FQRS was detected in more symptomatic post-COVID-19 patients than in patients in the asymptomatic group. Interestingly, although both groups had a history of COVID-19 infection, FQRS was detected in significantly more patients in the symptomatic group and was identified as an independent predictor. Another interesting aspect of our study is that even after more than 12 weeks had passed since the COVID-19 illness, the ECG findings of patients remain, even if they do not have a history of serious COVID-19.

### Limitations

Our research has several limitations. Since our initial sample size of 130 COVID-19 patients was small, a larger cohort study is needed to validate our findings. The absence of control (prior to COVID-19 infection) and/or recovery data is the study's main drawback. We will never know whether the COVID-19 infection is to blame for the prolongation or not.

### Conclusion

In summary, our investigation revealed that symptomatic post-COVID-19 patients exhibited a higher frequency of FQRS and smaller Tp-e intervals than asymptomatic post-COVID-19 patients. Furthermore, FQRS and Tp-e were identified as independent predictors in the symptomatic group (**Central Illustration**). We postulate that FQRS would be useful in identifying the subset of outpatient COVID-19 patients who have not experienced a severe illness and who might exhibit symptoms. Our results require long-term, large-scale research to be supported.

### References

1. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus Disease 2019 (COVID-19): Current Status and Future Perspectives. *Int J Antimicrob Agents*. 2020;55(5):105951. doi: 10.1016/j.ijantimicag.2020.105951.
2. Aedma SK, Mahajan P, Gadela NV, Okafor T, Patel M, Jadav R. Prevalence and Outcomes of Cardiovascular Complications Amongst Covid-19 Patients. *J Am Coll Cardiol*. 2021;77(18):3063. doi: 10.1016/S0735-1097(21)04418-1.
3. Raj SR, Arnold AC, Barboi A, Claydon VE, Limberg JK, Lucci VM, et al. Long-COVID Postural Tachycardia Syndrome: An American Autonomic Society Statement. *Clin Auton Res*. 2021;31(3):365-8. doi: 10.1007/s10286-021-00798-2.
4. Wu KC, Bhondokhan F, Haberlen SA, Ashikaga H, Brown TT, Budoff MJ, et al. Associations between QT Interval Subcomponents, HIV Serostatus, and Inflammation. *Ann Noninvasive Electrocardiol*. 2020;25(2):e12705. doi: 10.1111/anec.12705.

### Author Contributions

Conception and design of the research: Karakayalı M, Altunova M, Rencüzoğulları I; acquisition of data: Karakayalı M, Ilis D, Omar T, Guzel E; analysis and interpretation of the data and statistical analysis: Artac I, Karabağ Y; writing of the manuscript: Karakayalı M; critical revision of the manuscript for intellectual content: Karakayalı M, Altunova M, Rencüzoğulları I, Karabağ Y.

### Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

### Sources of Funding

There were no external funding sources for this study.

### Study Association

This study is not associated with any thesis or dissertation work.

### Ethics Approval and Consent to Participate

This study was approved by the Ethics Committee of the Faculty of Medicine of Kafkas University under the protocol number 80576354-050-99/177. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.

5. Arisoy A, Karaman K, Karayakalı M, Demirelli S, Seçkin HY, Çelik A, et al. Evaluation of Ventricular Repolarization Features with Novel Electrocardiographic Parameters (Tp-e, Tp-e/QT) in Patients with Psoriasis. *Anatol J Cardiol*. 2017;18(6):397-401. doi: 10.14744/AnatolJCardiol.2017.7901.
6. Das MK, Saha C, El Masry H, Peng J, Dandamudi G, Mahenthiran J, et al. Fragmented QRS on a 12-Lead ECG: A Predictor of Mortality and Cardiac Events in Patients with Coronary Artery Disease. *Heart Rhythm*. 2007;4(11):1385-92. doi: 10.1016/j.hrthm.2007.06.024.
7. Supreeth RN, Francis J. Fragmented QRS - Its Significance. *Indian Pacing Electrophysiol J*. 2020;20(1):27-32. doi: 10.1016/j.ipej.2019.12.005.
8. Yildirim A, Karaca IO, Yilmaz FK, Gunes HM, Cakal B. Fragmented QRS on Surface Electrocardiography as a Predictor of Cardiac Mortality in Patients with SARS-CoV-2 Infection. *J Electrocardiol*. 2021;66:108-12. doi: 10.1016/j.jelectrocard.2021.03.001.
9. Yenercağ M, Arslan U, Doğduş M, Günel Ö, Öztürk ÇE, Aksan G, et al. Evaluation of Electrocardiographic Ventricular Repolarization Variables in Patients with Newly Diagnosed COVID-19. *J Electrocardiol*. 2020;62:5-9. doi: 10.1016/j.jelectrocard.2020.07.005.
10. Brown RA, Schlegel TT. Diagnostic Utility of the Spatial versus Individual Planar QRS-T Angles in Cardiac Disease Detection. *J Electrocardiol*. 2011;44(4):404-9. doi: 10.1016/j.jelectrocard.2011.01.001.
11. Zhang ZM, Prineas RJ, Case D, Soliman EZ, Rautaharju PM; ARIC Research Group. Comparison of the Prognostic Significance of the Electrocardiographic QRS/T Angles in Predicting Incident Coronary Heart Disease and Total Mortality (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol*. 2007;100(5):844-9. doi: 10.1016/j.amjcard.2007.03.104.
12. Chua KC, Rusinaru C, Reinier K, Uy-Evanado A, Chugh H, Gunson K, et al. Tpeak-to-Tend Interval Corrected for Heart Rate: A More Precise Measure of Increased Sudden Death Risk? *Heart Rhythm*. 2016;13(11):2181-5. doi: 10.1016/j.hrthm.2016.08.022.
13. Antzelevitch C. T Peak-Tend Interval as an Index of Transmural Dispersion of Repolarization. *Eur J Clin Invest*. 2001;31(7):555-7. doi: 10.1046/j.1365-2362.2001.00849.x.
14. Çağdaş M, Karakoyun S, Rencüzoğulları İ, Karabağ Y, Yesin M, Velibey Y, et al. Assessment of the Relationship between Reperfusion Success and T-Peak to T-end Interval in Patients with ST Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention. *Anatol J Cardiol*. 2018;19(1):50-7. doi: 10.14744/AnatolJCardiol.2017.7949.
15. Tondas AE, Mulawarman R, Trifitriana M, Nurmaini S, Irfannuddin I. Arrhythmia Risk Profile and Ventricular Repolarization Indices in COVID-19 Patients: A Systematic Review and Meta-Analysis. *J Infect Dev Ctries*. 2021;15(2):224-9. doi: 10.3855/jidc.13922.
16. Tondas AE, Halım RA, Guyanto M. Minimal or no Touch Electrocardiography Recording and Remote Heart Rhythm Monitoring During COVID-19 Pandemic Era. *Medical J Indones*. 2020;41(2):133-41. doi: 10.30701/ijc.1010.
17. Sharma A, Jaiswal P, Kerakhan Y, Saravanan L, Murtaza Z, Zergham A, et al. Liver Disease and Outcomes Among COVID-19 Hospitalized Patients - A Systematic Review and Meta-Analysis. *Ann Hepatol*. 2021;21:100273. doi: 10.1016/j.aohep.2020.10.001.
18. Das MK, Khan B, Jacob S, Kumar A, Mahenthiran J. Significance of a Fragmented QRS Complex versus a Q Wave in Patients with Coronary Artery Disease. *Circulation*. 2006;113(21):2495-501. doi: 10.1161/CIRCULATIONAHA.105.595892.
19. Bektaş O, Çerik İB, Çerik HÖ, Karagöz A, Kaya Y, Dereli S, et al. The Relationship between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS - COV - 2) Pandemic and Fragmented QRS. *J Electrocardiol*. 2020;62:10-3. doi: 10.1016/j.jelectrocard.2020.07.009.
20. Özdemir İH, Özlek B, Özen MB, Gündüz R, Çetin N, Özlek E, et al. Fragmented QRS is a Marker of Mortality in Patients with Severe COVID-19: A Retrospective Observational Study. *Anatol J Cardiol*. 2021;25(11):811-20. doi: 10.5152/AnatolJCardiol.2021.62.

